Why Affimed Shares Are Soaring
Portfolio Pulse from Erica Kollmann
Affimed N.V. (NASDAQ:AFMD) shares surged after the company announced promising follow-up data from its AFM24-102 study in non-small cell lung cancer (NSCLC). The study showed significant efficacy in heavily pretreated patients, leading to a positive market reaction and a reiterated Buy rating from HC Wainwright & Co. with a $10 price target.
June 03, 2024 | 4:58 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Affimed's shares surged by 46.9% following the announcement of promising data from its AFM24-102 study in NSCLC. The study showed significant efficacy in heavily pretreated patients, leading to a positive market reaction. HC Wainwright & Co. reiterated its Buy rating with a $10 price target.
The positive follow-up data from the AFM24-102 study in NSCLC patients who failed previous treatments is a significant milestone for Affimed. The market reacted positively, with shares surging by 46.9%. Additionally, HC Wainwright & Co.'s reiterated Buy rating and $10 price target further support the bullish sentiment.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100